Vir Biotechnology stock hits 52-week low at $6.54

In a challenging year for biotech firms, Vir Biotechnology Inc (NASDAQ:VIR). shares have tumbled to a 52-week low, touching down at $6.54. According to InvestingPro data, technical indicators suggest the stock is currently oversold, while trading at just 0.79 times book value. The company, known for its focus on infectious diseases, has seen its stock price significantly retract from previous levels, reflecting a broader industry trend amidst a shifting healthcare landscape. Over the past year, Vir Biotechnology’s stock has experienced a notable decline, with a 1-year change showing a decrease of 35.25%. While the company maintains a strong liquidity position with a current ratio of 8.71 and more cash than debt on its balance sheet, InvestingPro analysis reveals additional insights through 10+ exclusive ProTips and comprehensive financial metrics available to subscribers.

In other recent news, Vir Biotechnology reported its fourth-quarter 2024 earnings, surpassing market expectations with a narrower-than-anticipated loss and significantly higher revenue. The company posted an earnings per share of -$0.76, which was better than the forecasted -$0.87, and revenue reached $12.37 million, exceeding the expected $8.14 million. Morgan Stanley (NYSE:MS) maintained its Overweight rating on Vir Biotechnology, reaffirming a $20 price target, as the company progresses with its Phase 3 ECLIPSE trials for chronic hepatitis delta. The trials aim to assess the efficacy and safety of the combination therapy of tobevibart and elebsiran, with the ECLIPSE-1 trial enrolling its first patient. Vir Biotechnology’s efforts in cost management were evident as R&D expenses dropped significantly to $57 million from $580 million the previous year. Additionally, general and administrative expenses decreased by 32% to $119 million. The company also plans to accelerate enrollment in its hepatitis delta program and advance its oncology initiatives, with further data expected by the end of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.